Particle.news

Download on the App Store

Serena Williams Confirms GLP‑1 Use, Reports 31‑Pound Loss

Her disclosure accompanies a paid partnership with telehealth provider Ro to destigmatize medically supervised weight‑loss drugs.

Image
Image
Image
Image

Overview

  • She began weekly injections in early 2024 after stopping breastfeeding her second child and says her blood sugar improved, knee pain eased and energy increased.
  • Williams reports experiencing no side effects, though doctors caution GLP‑1 drugs can cause nausea and other digestive issues for some patients.
  • She declined to name the specific medication; one outlet cited Zepbound in a Vogue interview, a detail not broadly confirmed elsewhere.
  • The announcement is tied to a new Ro campaign, and Williams serves as a paid ambassador while her husband Alexis Ohanian is an investor and board member at the company.
  • GLP‑1 agonists mimic a natural hormone that regulates appetite and blood sugar and are FDA‑approved for type 2 diabetes, with growing use for obesity alongside diet and exercise.